This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 205 Users Online

Mucopolysaccharidosis Mps Treatment Market

Mucopolysaccharidosis (MPS) Treatment Market - Global Industry Trend Analysis 2015 to 2019 and Forecast 2020 - 2028

Mucopolysaccharidosis (MPS) Treatment Market


Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases.” In MPS the mucopolysaccharides (sugar bound proteins) are not broken down correctly which causes products of incomplete metabolism to accumulate in the body. In MPS and other storage diseases, metabolic products that have not been eliminated have an impact on the functioning of cells, tissues and organs. The products typically accumulate, and cause symptoms, in different parts of the body.

One in 25,000 births, is estimated to be the prevalence of all forms of mucopolysaccharidosis. However, mucopolysaccharidoses, especially the milder forms of the diseases are often unrecognized, these disorders are under-diagnosed or misdiagnosed which makes it difficult to determine their true frequency in the general population.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Mucopolysaccharidosis (MPS) Treatment Market: Drivers and Restraints

Increase in no. of people suffering from lysosomal diseases and high burden of rare diseases   are expected to be the critical factors that may fuel the growth of the mucopolysaccharidosis (MPS) treatment market. The growing awareness regarding the novel therapies to treat mucopolysaccharidosis may boost the growth of mucopolysaccharidosis (MPS) treatment market. Moreover, the rise in research and development activities by key players for new therapeutics may also drive the growth of the market.  Additionally, the growing unmet clinical needs of patients along with better treatment outcomes may also help the mucopolysaccharidosis (MPS) treatment market to grow significantly.

However, complications and severity involved in the treatment of mucopolysaccharidosis (MPS) may hamper the growth of mucopolysaccharidosis (MPS) treatment market. High cost involved in the available treatment and lack of awareness among the rural population in underdeveloped and developing countries may also result in hindering the growth of mucopolysaccharidosis (MPS) treatment market. Another factor that may restrain the growth of mucopolysaccharidosis (MPS) treatment market is the delay associated with the diagnosis of mucopolysaccharidosis.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Mucopolysaccharidosis (MPS) Treatment Market: Segmentation

Based on disease type
  • Mucopolysaccharidosis (MPS) type I
  • Mucopolysaccharidosis (MPS) type II
  • Mucopolysaccharidosis  (MPS) type VI
  • Mucopolysaccharidosis (MPS) type IV A
  • others
Based on therapy type
  • Enzyme replacement therapy
  • Stem cell therapy
Based on distribution channel
  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies


Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Mucopolysaccharidosis (MPS) Treatment Market: Overview

In the disease type segment, Mucopolysaccharidosis (MPS) type I also known as hurler’s syndrome is one of the most severe type and has a higher presence among the population compared to other types.

In the therapy type segment, the mucopolysachharidosis (MPS) treatmement market is segmented into stem cell therapy and enzyme replacement therapy.

In this distribution channel segment, Retail pharmacies may dominate the market in terms of revenue but online pharmacies are expected to experience substantial growth during the forecast period due to the growing technological developments and increasing focus on convenience.

Mucopolysaccharidosis (MPS) Treatment Market: Regional-Wise Outlook

Geographically, the global mucopolysaccharidosis (MPS) treatment market is segmented into  5 regions, which is, North America, Latin America, Asia Pacific, Europe and Middle East & Africa.  

North America is expected to dominate the global market for mucopolysaccharidosis treatment during the forecast period. This can be attributed because of growing awareness among patient population regarding the advanced treatment options. Additionally, the presence of significant players and biopharmaceutical companies along with ongoing clinical trials may also drive the growth of mucopolysaccharidosis (MPS) treatment market.  

Europe is expected to have the 2nd largest market for mucopolysaccharidosis (MPS) treatment. However, Asia Pacific is expected experience significant market growth during the forecast periods as a result of untapped opportunities in this region. Moreover, the launch of novel therapeutics and the rising patient population may also boost the growth of mucopolysaccharidosis (MPS) treatment market in this region.

Mucopolysaccharidosis (MPS) Treatment Market: Key Players

Some of the players identified in the mucopolysaccharidosis (MPS) treatment market include:

  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Lupin
  • Pfizer Inc
  • Bayer AG
  • Cipla Inc.
  • Biomarin

The report covers exhaustive analysis on:

  • Mucopolysaccharidosis (MPS) Treatment Market Segments
  • Mucopolysaccharidosis (MPS) Treatment Market Dynamics
  • Historical Actual Market Size, 2013 - 2017
  • Mucopolysaccharidosis (MPS) Treatment Market Size & Forecast 2018 to 2024
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

- Companies Covered in This Report -

Google translate